Implication of CD35, CD21 and CD55 in Exudative Age-related Macular Degeneration

The recruitment status of this study is unknown because the information has not been verified recently.
Verified August 2010 by Rudolf Foundation Clinic.
Recruitment status was  Active, not recruiting
Sponsor:
Information provided by:
Rudolf Foundation Clinic
ClinicalTrials.gov Identifier:
NCT01174407
First received: November 19, 2008
Last updated: August 2, 2010
Last verified: August 2010

November 19, 2008
August 2, 2010
September 2008
December 2009   (final data collection date for primary outcome measure)
determine a possible implication of CD21, CD35 and CD55 in the pathogenesis of age-related macular degeneration [ Time Frame: 1 day ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT01174407 on ClinicalTrials.gov Archive Site
expression rates of on AMD-patients and a healthy control group [ Time Frame: 1 year ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
 
Implication of CD35, CD21 and CD55 in Exudative Age-related Macular Degeneration
Is CD35, CD21 and CD55 Associated With Exudative Age-related Macular Degeneration

The purpose of this study is to determine a possible implication of CD21, CD35 and CD55 in the pathogenesis of age-related macular degeneration. The aim is to asses a difference in expression rates of these factors on AMD-patients and a healthy control group.

Not Provided
Observational
Observational Model: Case Control
Time Perspective: Prospective
Not Provided
Not Provided
Non-Probability Sample

patients with exudative age-related macular degeneration, over 55

Age-Related Macular Degeneration
Other: cd 35, cd21, cd55
Blood drawing/ 10ml/ once- duration of 1 day of full examination of the patient
cd35
Intervention: Other: cd 35, cd21, cd55
Haas P, Aggermann T, Nagl M, Steindl-Kuscher K, Krugluger W, Binder S. Implication of CD21, CD35, and CD55 in the pathogenesis of age-related macular degeneration. Am J Ophthalmol. 2011 Sep;152(3):396-399.e1. doi: 10.1016/j.ajo.2011.02.017. Epub 2011 Jun 12.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
120
August 2010
December 2009   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Man and women over 18 years old
  • Filled out informed consent
  • Diagnosis of non-exudative/ exudative age related macular degeneneration

Exclusion Criteria:

  • Inherited retinal diseases
  • Other acquired retinal/ macular
  • Missing informed consent
Both
55 Years and older
Yes
Contact information is only displayed when the study is recruiting subjects
Austria
 
NCT01174407
EK08010-VK
No
Prof. Dr. Susanne Binder, Rudolf Foundation Clinic
Rudolf Foundation Clinic
Not Provided
Not Provided
Rudolf Foundation Clinic
August 2010

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP